CDK4/6 inhibitors selectively inhibit CDK4/6, effectively preventing tumor cells from progressing from G1 phase to S phase, restoring cell cycle control, and blocking tumor cell proliferation [21–23]. Here, CDK4 is linked to neoplasm.